Comparison of anticoagulation monitoring strategies for adults supported on extracorporeal membrane oxygenation: A systematic review.

[1]  A. Bello,et al.  Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation. , 2022, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[2]  J. Beller,et al.  Discordance among assays for monitoring? Anticoagulation during extracorporeal life support , 2022, Perfusion.

[3]  T. Staudinger,et al.  How to manage anticoagulation during extracorporeal membrane oxygenation , 2022, Intensive Care Medicine.

[4]  He Huang,et al.  The Efficacy and Safety of Bivalirudin Versus Heparin in the Anticoagulation Therapy of Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis , 2022, Frontiers in Pharmacology.

[5]  E. Fan,et al.  2021 ELSO Adult and Pediatric Anticoagulation Guidelines. , 2022, ASAIO journal.

[6]  Hieu Trung Kieu,et al.  Major Bleeding in Adults Undergoing Peripheral Extracorporeal Membrane Oxygenation (ECMO): Prognosis and Predictors , 2022, Critical care research and practice.

[7]  Hua Jiang,et al.  Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis , 2021, Thrombosis Research.

[8]  Kai Song,et al.  A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy , 2021, Hämostaseologie.

[9]  L. Baumann Kreuziger,et al.  Heparin Monitoring with an Anti-Xa Protocol Compared to Activated Clotting Time in Patients on Temporary Mechanical Circulatory Support , 2021, The Annals of pharmacotherapy.

[10]  J. Menaker,et al.  A Comparison of Anticoagulation Strategies in Veno-venous Extracorporeal Membrane Oxygenation , 2021, ASAIO journal.

[11]  A. Charles,et al.  Evaluation of a Multimodal Heparin Laboratory Monitoring Protocol in Adult Extracorporeal Membrane Oxygenation Patients , 2021, Journal of pharmacy practice.

[12]  R. Serra,et al.  Systematic review and meta-analysis of the clinical effectiveness of point-of-care testing for anticoagulation management during ECMO. , 2021, Journal of clinical anesthesia.

[13]  S. Susen,et al.  Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study , 2021, Journal of clinical medicine.

[14]  O. McCarty,et al.  Heparin Resistance Is Common in Patients Undergoing Extracorporeal Membrane Oxygenation but Is Not Associated with Worse Clinical Outcomes , 2021, ASAIO journal.

[15]  X. T. Phan,et al.  Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA? , 2021, Critical care research and practice.

[16]  K. Maher,et al.  Measures of anticoagulation and coagulopathy in pediatric cardiac extracorporeal membrane oxygenation patients , 2020, The International journal of artificial organs.

[17]  Hesham S. Al-Sallami,et al.  The Influence of Haemostatic System Maturation on the Dose–Response Relationship of Unfractionated Heparin , 2020, Clinical Pharmacokinetics.

[18]  H. ten Cate,et al.  Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO , 2020, TH Open.

[19]  T. Owaidah,et al.  Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator , 2020, The Annals of pharmacotherapy.

[20]  G. Grasselli,et al.  A Randomized Controlled Trial of Antithrombin Supplementation During Extracorporeal Membrane Oxygenation , 2020, Critical care medicine.

[21]  A. Willems,et al.  Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis , 2020, Perfusion.

[22]  J. Geli,et al.  Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review , 2020, Journal of intensive care medicine.

[23]  W. Dager,et al.  Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients. , 2020, ASAIO journal.

[24]  Stein Silva,et al.  Anticoagulation Monitoring Under ECMO Support: A Comparative Study Between the Activated Coagulation Time and the Anti-Xa Activity Assay , 2020, Journal of intensive care medicine.

[25]  G. Foti,et al.  Thromboelastometry, Thromboelastography, and Conventional Tests to Assess Anticoagulation During Extracorporeal Support: A Prospective Observational Study. , 2020, ASAIO journal.

[26]  Diana Altshuler,et al.  Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support , 2020, ASAIO journal.

[27]  S. Uezono,et al.  Coagulation assessment with thromboelastography during abdominal endovascular aneurysm repair in a patient with hemophilia A , 2020, JA clinical reports.

[28]  S. Price,et al.  Why we need safer anticoagulant strategies for patients on short-term percutaneous mechanical circulatory support , 2020, Intensive Care Medicine.

[29]  K. Anger,et al.  Activated Clotting Times Demonstrate Weak Correlation With Heparin Dosing in Adult Extracorporeal Membrane Oxygenation , 2019, American journal of therapeutics.

[30]  S. Chatterjee,et al.  Evaluation of a heparin monitoring protocol for extracorporeal membrane oxygenation and review of the literature. , 2019, Journal of thoracic disease.

[31]  B. Griffith,et al.  Bleeding, Thrombosis, and Transfusion With Two Heparin Anticoagulation Protocols in Venoarterial ECMO Patients. , 2019, Journal of cardiothoracic and vascular anesthesia.

[32]  A. Pesenti,et al.  Antithrombin During Extracorporeal Membrane Oxygenation in Adults: National Survey and Retrospective Analysis , 2019, ASAIO journal.

[33]  M. D. de Maat,et al.  Monitoring of heparins in antithrombin-deficient patients. , 2019, Thrombosis research.

[34]  A. Hvas,et al.  Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients: A Systematic Review , 2018, Front. Cardiovasc. Med..

[35]  D. Brodie,et al.  Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome , 2018, The New England journal of medicine.

[36]  J. Kalbhenn,et al.  Bleeding during veno-venous ECMO cannot reliably be predicted by rotational thrombelastometry (ROTEM™) , 2018, Perfusion.

[37]  G. Grasselli,et al.  Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study , 2018, Annals of Intensive Care.

[38]  F. Masud,et al.  Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients , 2017, Perfusion.

[39]  R. Sanderson,et al.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy , 2017, The FEBS journal.

[40]  M. Bailey,et al.  Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation , 2016, Annals of Intensive Care.

[41]  S. Chon,et al.  Activated clotting time test alone is inadequate to optimize therapeutic heparin dosage adjustment during post-cardiopulmonary resuscitational extracorporeal membrane oxygenation (e-CPR) , 2016, Perfusion.

[42]  D. Consonni,et al.  Prevalence of “Flat-Line” Thromboelastography During Extracorporeal Membrane Oxygenation for Respiratory Failure in Adults , 2016, ASAIO journal.

[43]  A. Vuylsteke,et al.  Agreement between ACT and aPTT during extracorporeal membrane oxygenation shows intra- and inter-individual variation , 2016, Perfusion.

[44]  I. Martinelli,et al.  Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. , 2016, Minerva anestesiologica.

[45]  S. Bihari,et al.  Discordance between ROTEM® clotting time and conventional tests during unfractionated heparin–based anticoagulation in intensive care patients on extracorporeal membrane oxygenation , 2016, Anaesthesia and intensive care.

[46]  P. Jansz,et al.  Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. , 2015, Journal of cardiothoracic and vascular anesthesia.

[47]  F. Masud,et al.  Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients , 2014, Perfusion.

[48]  P. Guida,et al.  Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery. , 2013, Journal of cardiothoracic and vascular anesthesia.

[49]  A. Hotta,et al.  Ultrastructural characterization of surface‐induced platelet activation on artificial materials by transmission electron microscopy , 2013, Microscopy research and technique.

[50]  Klaus Görlinger,et al.  Coagulation management in patients undergoing mechanical circulatory support. , 2012, Best practice & research. Clinical anaesthesiology.

[51]  T. Vondracek,et al.  Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin , 2012, Pharmacotherapy.

[52]  Susanna Price,et al.  Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). , 2011, JAMA.

[53]  W. Oliver.  Anticoagulation and Coagulation Management for ECMO , 2009, Seminars in cardiothoracic and vascular anesthesia.

[54]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[55]  F. Pigula,et al.  Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. , 2007, The Annals of thoracic surgery.

[56]  A. Burroughs,et al.  The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[57]  J. Weiler,et al.  Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. , 1997, Journal of cardiothoracic and vascular anesthesia.

[58]  E. Spitznagel,et al.  Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[59]  P. Powers,et al.  Development of the human coagulation system in the full-term infant. , 1987, Blood.

[60]  F. Shann,et al.  Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate? , 2007, Thrombosis research.

[61]  J. Weitz,et al.  Coagulation assays. , 2005, Circulation.